Cover Image
市場調查報告書

非侵入性癌症診斷的各種技術、全球市場

Noninvasive Cancer Diagnostics: Technologies and Global Markets

出版商 BCC Research 商品編碼 545439
出版日期 內容資訊 英文 335 Pages
訂單完成後即時交付
價格
Back to Top
非侵入性癌症診斷的各種技術、全球市場 Noninvasive Cancer Diagnostics: Technologies and Global Markets
出版日期: 2017年08月22日 內容資訊: 英文 335 Pages
簡介

2016年,全球非侵入性癌症診斷的市場達到了1074億美元的規模。該市場預計從2017年到2022年以6.9%的年複合成長率發展,從2017年的約1146億美元,成長到2022年的1598億美元的規模。

本報告提供全球非侵入性癌症診斷的市場調查,主要技術、產品概要,主要企業的配合措施,癌症的罹患率、盛行率、死亡率的統計,癌症的各類型、技術、終端用戶、地區/主要國家的市場規模的變化與預測,市場的各種影響因素分析,法律制度,專利資料,以及主要企業的簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術的檢討:診斷影像

  • 使用了Raman光譜學的即時體外癌症診斷
  • 個性化癌症診斷的體外螢光影像
    • 直接影像
    • 間接螢光影像
  • MRI掃描
    • RF子系統的開發
  • PET掃描
  • PET/MRI
  • 乳房X光攝影
    • 數位乳房X光攝影系統
    • 乳房斷層攝影系統
  • 超音波
  • 食道造影、灌腸
  • 骨掃描 (MRI、CT、PET)
    • 市場估計

第4章 市場、技術的檢討:非侵入性先進癌症診斷化驗、技術

  • 簡介:循環核酸 (CNA)
  • 診斷工具的CNA
    • 癌症生物標記的循環DNA
    • 產前診斷的循環DNA的利用 (傳統)
    • 產前診斷的循環DNA的利用 (非侵入性)
    • 生物標記的循環RNA
    • 循環核酸檢測法
  • 液態切片
    • Janssen Diagnostics
    • Roche Molecular Systems Inc.
    • Genomic Health
    • Foundation Medicine
    • Veracyte
    • Trovagene Inc.
    • Myriad Genetics
    • OncoCyte Corp.
    • Illumina
    • NeoGenomics Laboratories
    • Biocept Inc.
    • Vermillion Inc.
    • Sysmex Inostics
    • Guardant Health
    • 產品開發、新倡議
  • 分子細胞遺傳/基因表現研究
    • 少量的RNA的放大、檢測
    • 數百遺傳基因的分析
    • 蛋白質體學、新的蛋白質標記
    • ProteinChip系統
    • 蛋白質組模式認識
  • 次世代定序 (NGS) 研究
    • Illumina:Solexa System
    • Roche:454 Sequencing
    • Thermo Fisher:Scientific Ion PGM (Personal Genome Machine)
    • Thermo Fisher:Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
    • Oxford Nanopore Technologies
    • 第3代定序器
    • 新的診斷化驗的臨床性接受
  • 由於唾液的口服癌症診斷
  • 先進組織染色 (IHC、ISH)
    • 光活體組織切片
    • 市場估計

第5章 市場、技術的檢討:非侵入性傳統癌症診斷化驗、實驗

  • 子宮頸抹片檢查、HPV試驗
  • 腫瘤生物標記檢驗
    • MammaPrint規格
    • Genomic Health:Oncotype DX乳癌檢驗
    • Prosigna:Breast Cancer Prognostic Gene Signature Assay (舊稱PAM50)
    • 癌症診斷測試銷售、行銷策略
  • FOBT (糞便潛血反應檢驗)
  • DRE (數位直腸檢驗)
  • MUGA (多閘極掃描)
  • 市場估計

第6章 癌症的罹患率、盛行率、死亡率的統計:全球市場摘要

  • 關於疾病
  • 罹患率、盛行率的統計分析
    • 各主要癌症類型
  • 各地區模式
    • 歐洲
    • 北美
    • 亞太地區
    • 中南美
    • 中東/非洲
  • 對癌症的負擔、癌症的風險要素
    • 香煙消費和癌症
    • 酒精消費和癌症
    • 肥胖和癌症
    • 感染疾病和癌症
    • 遺傳基因/遺傳疾病和癌症
    • 太陽光、紫外線和癌症
    • 荷爾蒙和癌症

第7章 市場分析:各癌症類型

  • 全球市場:各癌症類型
    • 成長推動因素
    • 阻礙成長要素
  • 北美
    • 主要的成長推動因素
    • 主要的阻礙成長要素
    • 主要國家
  • 歐洲
    • 主要的成長推動因素
    • 主要的阻礙成長要素
    • 主要國家
  • 亞太地區
    • 主要的成長推動因素
    • 主要的阻礙成長要素
    • 主要國家
  • 中南美
    • 主要的成長推動因素
    • 主要的阻礙成長要素
    • 主要國家
  • 中東/非洲
    • 主要的成長推動因素
    • 主要的阻礙成長要素
    • 主要國家

第8章:市場分析:各技術、終端用戶

  • 全球市場:各技術
  • 全球市場:各終端用戶

第9章:技術的發展、趨勢、市場機會

  • 診斷影像
  • 先進非侵入性方法
  • 篩檢化驗

第10章:法律規章必要條件

  • 美國
  • 歐洲
  • 日本
  • 中國
  • 印度
  • 韓國
  • 巴西
  • 阿根廷
  • 墨西哥

第11章 專利檢討

第12章 企業簡介

關於BCC Research

圖表

目錄
Product Code: HLC197A

Report Highlights

The global market for noninvasive cancer diagnostics was valued at $107.4 billion in 2016. This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.

Report Includes:

  • An overview of the global noninvasive cancer diagnostics market.
  • Analyses of global market trends, with data from 2016, estimates for 2017 and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis of the market by principle technology and by geography.
  • Detailed breakdown of advanced non-invasive approaches.
  • Coverage of segmentation of the cell-free DNA diagnostic methods.
  • A look at major factors driving the growth of the non-invasive cancer diagnostic and technologies market.
  • Profiles of major players in the industry.

Report Scope

The aim of this report is to initially conduct a review of the noninvasive cancer diagnostics products currently available; assess the market potential by clinical application; examine statistics on the incidence and mortality of cancer; review the issues facing the use of noninvasive cancer diagnostics; and review some of the latest developments into new and innovative noninvasive cancer diagnostic products, their technologies, and their intended clinical applications.

Key objectives are to conduct and provide an analysis of the market value, growth rates, market shares, and market development, as well as examine the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

  • A detailed analysis of the revenues and forecasts for the global noninvasive cancer diagnostics market with a further, more detailed analysis and forecast of the revenues for the global market subdivided by major market subsegments by geographic region and finally by selected country.
  • A detailed analysis of the global market share, together with a further, more detailed analysis of the market share by geographic region and finally by selected country.

    In addition, this analysis provides a:

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of noninvasive cancer diagnostics and related products, together with related information about specific products.

The study will allow the reader to:

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the noninvasive cancer diagnostics market.
  • Investigate the current market dynamics that are driving change in the noninvasive cancer diagnostics market.
  • Assess future growth opportunities in the noninvasive cancer diagnostics market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Utilize the report to help realize a company's position in the marketplace and to provide insight into the future of the market and the opportunities that exist.

Analyst Credentials

PAUL TAYLOR is an independent market researcher and analyst focused on the medical industry. He previously worked for multinational medical device companies on strategic business and marketing plans. His predictive analytics knowledge and models of market research data have been used for biopharmaceutical and biotechnology clients. He has a bachelor's degree and Ph.D. degree in biochemistry from the University of Liverpool and an MBA degree for Oxford Brookes University.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology and Information Sources
    • Primary Data and Information Gathering
    • Secondary Data and Information Gathering
    • Market Share Analysis and Market Forecast Prediction
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Summary of Key Findings
    • Diagnostic Imaging Segment
    • Advanced Diagnostics Segment
    • Conventional Segment

Chapter 3: Market and Technology Review: Diagnostic Imaging

  • Real-time In Vivo Cancer Diagnosis using Raman Spectroscopy
  • In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics
    • Direct Imaging
    • Indirect Fluorescence Imaging
  • Magnetic Resonance Imaging (MRI) Scans
    • Development to the RF Subsystem
  • Positron Emission Tomography (PET) Scan
  • Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
  • Mammography
    • Digital Mammography Systems
    • Breast Tomosynthesis Systems
  • Ultrasound
  • Barium Swallow or Enema
  • Bone Scans (MRI, CT and PET)
    • Market Estimate

Chapter 4: Market and Technology Review: Advanced Noninvasive Cancer Diagnostic Assays and Technologies

  • Introduction to Circulating Nucleic Acids (CNAs)
  • Circulating Nucleic Acids as a Diagnostic Tool
    • Circulating DNA as a Biomarker of Cancer
    • Use of Circulating DNA for Prenatal Diagnosis (Conventional)
    • Use of Circulating DNA for Prenatal Diagnosis (Noninvasive)
    • Circulating RNA as a Biomarker of Cancer
    • Methods Used for the Detection of Circulating Nucleic Acids
  • Liquid Biopsy
    • Janssen Diagnostics
    • Roche Molecular Systems Inc.
    • Genomic Health
    • Foundation Medicine
    • Veracyte
    • Trovagene Inc.
    • Myriad Genetics
    • OncoCyte Corp.
    • Illumina
    • NeoGenomics Laboratories
    • Biocept Inc.
    • Vermillion Inc.
    • Sysmex Inostics, a subsidiary of Sysmex Corp.
    • Guardant Health
    • Product Development and New Initiatives in Liquid Biopsy
  • Molecular Cytogenetic/Gene Expression Studies
    • Amplify and Detect Diminished Amounts of RNA Consistently
    • Analyze Hundreds of Genes
    • Proteomics and New Protein Markers
    • Inside the ProteinChip System
    • Proteome Pattern Recognition
  • Next-Generation Sequencing (NGS) Studies
    • Illumina Solexa System
    • Roche 454 Sequencing
    • Thermo Fisher Scientific Ion Personal Genome Machine (PGM)
    • Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
    • Oxford Nanopore Technologies
    • The Third-Generation Sequencer
    • Clinical Acceptance of a New Diagnostic Assay
  • Saliva-Based Oral Cancer Diagnostics
  • Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))
    • Optical Biopsy
    • Market Estimate

Chapter 5: Market and Technology Review: Conventional Noninvasive Cancer Diagnostic Assays and Tests

  • Pap Test and HPV Testing
  • Tumor Biomarker Testing
    • MammaPrint Specifications
    • Genomic Health's Oncotype DX Breast Cancer Test
    • The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)
    • Sales and Marketing Strategies for Cancer Tests
  • Fecal Occult Blood Tests (FOBT)
  • Digital Rectal Exam (DRE)
  • Multigated Acquisition (MUGA) Scans
  • Market Estimate

Chapter 6: Incidence, Prevalence and Mortality Statistics for Cancer: A Global Summary

  • Cancer: The Disease
  • Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
    • Incidence and Prevalence Rates for Major Cancer Types
  • Regional Patterns of Cancer
    • Europe
    • North America
    • Asia-Pacific
    • Latin and Central America
    • Middle East/Africa
  • The Global Cancer Burden and Worldwide Cancer Risk Factors
    • Tobacco Use and Statistics
    • Alcohol Abuse and Cancer Statistics
    • Obesity and Cancer Statistics
    • Infectious Diseases and Cancer
    • Inherited Genes/Diseases and Cancer
    • Sun, U.V. and Cancer
    • Hormones and Cancer

Chapter 7: Noninvasive Cancer Diagnostics Market by Cancer Type

  • Global Noninvasive Cancer Diagnostics Market, by Cancer Type
    • Global Market Drivers
    • Global Market Restraints
  • Regional Noninvasive Cancer Diagnostics Market Assessment: North America
    • Selected Market Drivers: North America
    • Selected Market Restraints: North America
    • Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Europe
    • Selected Market Drivers: Europe
    • Selected Market Restraint: Europe
    • Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Asia-Pacific
    • Selected Market Drivers: Asia-Pacific
    • Selected Market Restraints: Asia-Pacific
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America
    • Selected Market Drivers: Central and Latin America
    • Selected Market Restraints: Central and Latin America
  • Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa
    • Selected Market Drivers: Middle East/Africa
    • Selected Market Restraints: Middle East/Africa

Chapter 8: Market Analysis by Technology, End User and Market Share

  • Global Noninvasive Cancer Diagnostics Market, by Technology
    • Regional Noninvasive Cancer Diagnostics Market, by Technology: North America
    • Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe
    • Regional Noninvasive Cancer Diagnostics Market, by Technology: Asia-Pacific
    • Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America
    • Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa
  • Global Noninvasive Cancer Diagnostics Market, by End-User
    • General Clinical Reference Laboratories
    • Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market

Chapter 9: Technological Advances, Trends and Opportunities

  • Key Technological Developments and Advances, Market Trends and Opportunities
    • Developments and Advances, Trends and Opportunities in Diagnostic Imaging
    • Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches
    • Developments and Advances, Trends and Opportunities in Screening Assays
    • Opportunities for IVDMIA Companies

Chapter 10: Regulatory and Legislative Requirements

  • United States
    • How are IVDs Classified?
    • FDA Regulations Relating to Companion Diagnostics
    • Laboratory Developed Tests (LDTs)
    • Centers for Medicare & Medicaid Services (CMS)
    • The 2010 Affordable Care Act
    • Private Insurance
  • Europe
    • (General) Medical Device Directive, MDD (93/42/EEC)
    • Active Implantable Medical Device Directive, AIMDD (90/383/EEC
    • In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
    • Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)
  • Japan
    • Marketing Authorization System
  • China
    • Overview of the Healthcare System
    • Healthcare Reforms
    • Healthcare Institutions
  • India
    • Overview of the Healthcare System
    • Hospital Resources
    • Population Statistics
  • South Korea
  • Brazil
    • Background
    • Regulatory and Legislative Requirements
    • Market Entry and Reimbursement of Medical Devices: Brazil
  • Argentina
    • Background
    • Government-funded Public Health Sector
    • Social Health Insurance Sector
    • Private Sector
    • Regulatory and Legislative Requirements
  • Mexico
    • Legislation and Regulations Governing Medical Devices in Mexico
    • Health Insurance Structure in Mexico

Chapter 11: Patent Review of Key Technologies

  • Microarray Patents
  • LOAC Patents
  • Clinical Next-Generation Sequencing (NGS) Patents
    • Clinical NGS Patents Summary
    • Clinical NGS Patents by Indication

Chapter 12: Company Profiles

Appendix A: Company Addresses and Contact Details

Appendix B: Government Regulatory Agencies and Professional Organizations

Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 1: Diagnostic Imaging Segment
    • Table 2: Advanced Segment
    • Table 3: Conventional Segment
    • Table 4: Noninvasive Cancer Diagnostics Market Segmentation
    • Table 5: Breast MRI Systems Currently Available
    • Table 6: Wide Bore MRI Systems Currently Available
    • Table 7: PET/CT Systems Currently Available
    • Table 8: PET/MR Systems Currently Available
    • Table 9: Key trends in (Digital Mammography Systems)
    • Table 10: Digital Mammography Systems Currently Available
    • Table 11: Breast Tomosynthesis Systems Currently Available
    • Table 12: Benefits of Medical Ultrasound Imaging
    • Table 13: Regulatory Approval for High-intensity Focused Ultrasound (HIFU) by Region
    • Table 14: Ultrasound Systems Currently Available
    • Table 15: Noninvasive Cancer Diagnostics Market Segmentation
    • Table 16: Major Developments in Understanding Nucleic Acids and their Cellular Roles
    • Table 17: Circulating Tumor-associated miRNAs as Potential Cancer Biomarkers
    • Table 18: Key Elements for Business Competition in Gene Expression Profiling for Cancer
    • Table 19: DNA Microarray Diagnostic Test Adoption Rate
    • Table 20: Characteristics of in situ Hybridization Methods
    • Table 21: Key Advantages of Optical Biopsy Systems
    • Table 22: Noninvasive Cancer Diagnostics Market Segmentation
    • Table 23: Key Drivers to Adoption of Biomarkers in Clinical Use
    • Table 24: Key Barriers to Adoption of Biomarkers in Clinical Use
    • Table 25: Tumor Biomarkers Currently in Common Clinical Use
    • Table 26: MammaPrint: Key Features
    • Table 27: Strategies for Marketing Cancer Diagnostic Products
    • Table 28: Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
    • Table 29: Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
    • Table 30: Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence, 2012
    • Table 31: Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (In Men and Women Combined) by Cancer Type, 2012
    • Table 32: Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Men) Cancer Type, 2012
    • Table 33: Summary Statistics (Global): Estimated Incidence, Mortality and Five-Year Prevalence (Women) by Cancer Type, 2012
    • Table 34: Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)
    • Table 35: Estimated Number of Deaths from Cancer by Sex: United States, 2017
    • Table 36: Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions)
    • Table 37: Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 38: Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
    • Table 39: Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
    • Table 40: North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 41: Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing
    • Table 42: United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 43: Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 44: European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 45: Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
    • Table 46: France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 47: Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 48: Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 49: Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 50: U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 51: Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 52: Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 53: Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 54: Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 55: Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
    • Table 56: China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 57: India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
    • Table 58: Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
    • Table 59: South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 60: Rest of Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 Millions)
    • Table 61: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 62: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
    • Table 63: Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 64: Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 65: Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 66: Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 67: Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 68: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022($ Millions)
    • Table 69: Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
    • Table 70: Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 71: Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 72: Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 73: Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 74: Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 75: Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions)
    • Table 76: North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 77: North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 78: North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 79: North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
    • Table 80: Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 81: Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 82: Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 83: Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
    • Table 84: Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 85: Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 86: Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 87: Asia-Pacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
    • Table 88: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
    • Table 89: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 90: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 91: Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
    • Table 92: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 Millions)
    • Table 93: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
    • Table 94: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
    • Table 95: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
    • Table 96: Global Noninvasive Cancer Diagnostics Market, by End-User, Through 2022 ($ Millions)
    • Table 97: Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 98: Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 99: Global Market Share for Molecular Signature-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 100: Global Market Share for DNA Microarray-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 101: Global Market Share for Cytogenetic/Gene Expression-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 102: Global Market Share for Circulating Nucleic Acid (CNA)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 103: Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 104: Global Market Share for Fecal Occult Blood Test (FOBT)-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 105: Global Market Share for Tumor Biomarker Test-Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
    • Table 106: Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017
    • Table 107: Uses of Tumor Biomarkers in Drug Development
    • Table 108: Utility of Biomarkers as Companion Diagnostics to Drug Development
    • Table 109: Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD
    • Table 110: Number of Healthcare Institutions According to Ownership in China, 2010
    • Table 111: Total Number of Hospitals by Ranking in China, 2010
    • Table 112: Overview of Healthcare in India
    • Table 113: DNA Microarray Patents by Region, 2002-2012
    • Table 114: Microarray-Related Proteomics Patents by Region, 2002 -- 2012
    • Table 115: Microarray-Related Patents by Application and Title, 2017
    • Table 116: Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 -- Present
    • Table 117: LOAC-Related Proteomics Patents by Region, 2002 -- 2012
    • Table 118: LOAC-Related Patents by Appli cation and Title, 2013 - 2015
    • Table 119: Clinical Next Generation Sequencing Patents, 2002-2012
    • Table 120: Clinical NGS-Related Patents by Application and Title, 2013 - 2015
    • Table 121: Clinical NGS Patents by Indication, 2002-2012
    • Table 122: Abbott Laboratories: Company Financials, Through 2016 ($ Millions)
    • Table 123: Bayer AG: Company Financials, Through 2016 ($ Millions)
    • Table 124: bioMerieux S.A. Sales by Application, Through 2016 ($ Millions)
    • Table 125: Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%)
    • Table 126: Hologic Inc.: Company Financials, 2015-2016 ($ Millions)
    • Table 127: Illumina, Inc: Company Financials, 2014-2016 ($ Millions)
    • Table 128: Myriad Genetics Inc. Financials, 2014 - 2016 ($ Millions)
    • Table 129: Philips Healthcare Financials, Through 2016 ($ Millions)
    • Table 130: Philips Group Financials by Segment, 2016 ($ Millions)
    • Table 131: Qiagen N.V. Financials, Through 2016 ($ Millions)
    • Table 132: Qiagen N.V. Financials by Region, Through 2016 ($ Millions)
    • Table 133: Quest Diagnostics Financials, Through 2016 ($ Millions)
    • Table 134: Roche Group Financials, Through 2016 ($ Millions)
    • Table 135: Diagnostics Division Financials, 2015 and 2016 ($ Millions)
    • Table 136: Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions)
    • Table 137: Company Addresses and Contact Details
    • Table 138: Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics
    • Table 139: Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics

List of Figures

  • Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 2016-2022 ($ Millions)
    • Figure 1: Top Molecular CNA Characterization Techniques (%)
    • Figure 2: Market Growth and Evolution of MDx Cancer Biomarkers
    • Figure 3: Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)
    • Figure 4: Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)
    • Figure 5: Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)
    • Figure 6: Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)
    • Figure 7: Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
    • Figure 8: Average Number of New Cases per Year and Age-Specific Incidence Rates for all Cancers in the U.K., 2012-2014
    • Figure 9: Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
    • Figure 10: Asia-Pacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
    • Figure 11: Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017
    • Figure 12: Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
    • Figure 13: Global Noninvasive Cancer Diagnostics Market, by Technology Type, 2016-2022 ($ Millions)
    • Figure 14: Global Noninvasive Cancer Diagnostics Market, by End-User, 2016-2022 ($ Millions)
    • Figure 15: Tumor Biomarker Developments and Market Applications (%)
    • Figure 16: Private Health Insurance Coverage among Persons Under 65 in United States, 2007-2011 (Millions/Percent)
    • Figure 17: The Chinese Healthcare System
Back to Top